31 March 2026 |
Blog, Campaigning and research, News, Treatments
Vorasidenib is a targeted therapy in tablet form. It works by inhibiting mutated IDH1 and IDH2 enzymes, which can drive tumour growth in some low-grade gliomas such as astrocytoma and oligodendroglioma.
Clinical trial evidence has shown that the drug can delay tumour progression and may help postpone the need for treatments such as radiotherapy and chemotherapy for some patients. The decision from NICE gives access to Vorasidenib for people aged 12 or older and will depend on certain criteria and be determined by a patient’s clinical team. If you think this treatment may be relevant to you or a loved one, we encourage you to speak with them. Access may take a little time to become fully established across all centres, but your team will be able to advise on availability.
We understand that news like this can bring both hope and also raise questions. Our team is here to support you, if you would like to speak to someone, please get in touch with your Support Professional, contact our support line on 01454 422 701, or email support@braintumoursupport.co.uk.
21 May 2026
When someone is diagnosed with a brain tumour, they may be overwhelmed by the need to understand a new language. This article aims to provide a shortcut to that new language so that patients, caregivers, colleagues, employers, journalists, policymakers and…
Read
26 February 2026
When we tell people that brain tumours are the biggest cancer killer of the under 40s, their first reaction is often shock or disbelief. What’s the evidence for this and where do we get our figures from?
Read
13 January 2026
We know that many people in our community are eagerly anticipating NICE’s decision on NHS funding for Vorasidenib. Yesterday, 12 January, it was announced that the appraisal for the drug has been paused, at the request of the drug’s manufacturer,…
Read
19 October 2025
Liam Vincent-Kilbride was diagnosed with a grade 2 glioma, and following surgery in October 2024 was offered to be part of the Early Access Program, taking Vorasidenib. After 10 months on the drug, he shared his experience and reaction in…
Read